Regencell Bioscience (NASDAQ:RGC – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, FiscalAI reports.
Regencell Bioscience Price Performance
RGC opened at $7.63 on Friday. Regencell Bioscience has a 52-week low of $4.51 and a 52-week high of $69.00. The business’s fifty day moving average is $5.95 and its 200-day moving average is $14.79.
Analyst Ratings Changes
Several research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, September 21st. Wall Street Zen cut Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Institutional Investors Weigh In On Regencell Bioscience
Several institutional investors and hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience during the fourth quarter worth about $92,000. Amundi bought a new position in Regencell Bioscience in the 1st quarter valued at about $219,000. Finally, Bank of America Corp DE raised its position in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares in the last quarter. Institutional investors own 0.13% of the company’s stock.
Regencell Bioscience Company Profile
Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.
The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.
Further Reading
- Five stocks we like better than Regencell Bioscience
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
